{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.1","value":"147.9"},{"groupId":"OG001","spread":"27.8","value":"163.6"},{"groupId":"OG002","spread":"24.4","value":"159.2"},{"groupId":"OG003","spread":"19.9","value":"156.6"},{"groupId":"OG004","spread":"35.6","value":"126.9"},{"groupId":"OG005","spread":"30.5","value":"145.3"},{"groupId":"OG006","spread":"16.3","value":"167.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG000","title":"CTX-471 Monotherapy 0.1 mg/kg"},{"description":"0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG001","title":"CTX-471 Monotherapy 0.3 mg/kg"},{"description":"0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG002","title":"CTX-471 Monotherapy 0.6 mg/kg"},{"description":"1.2 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG003","title":"CTX-471 Monotherapy 1.2 mg/kg"},{"description":"0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG004","title":"CTX-471 Combination 0.1 mg/kg"},{"description":"0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG005","title":"CTX-471 Combination 0.3 mg/kg"},{"description":"0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG006","title":"CTX-471 Combination 0.6 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Analysis Set: all patients who received CTX-471 (and pembrolizumab in combination arms) and had at least 1 post-treatment measurement and no protocol deviations or events affecting the validity of the results","reportingStatus":"POSTED","timeFrame":"Calculated from plasma concentrations measured from samples collected before the first dose of CTX-471; 1, 6, and 24 hours after the first dose of CTX-471; and before the second dose of CTX-471 (Weeks 1 to 3)","title":"Half-life (t1/2) of Serum Concentration of CTX-471","type":"SECONDARY","unitOfMeasure":"hours"}